UTMD

AI MemoPost-earnings T+3

Utah Medical Products

As of 2026-07-31/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings confirm revenue-replacement shortfall • 2026-07-31

Base target: $72 / p=50% prob

Biggest risk

The post-earnings evidence is fundamentally cautious: revenue remains below prior year, replacement sales are slower than expected, neonatal and Filshie sales were weak, and litigation costs increased. Analyst revisions, consensus surprise data, and target changes are unavailable.

Invalidation

Break below $58 or thesis failure.

What would change my mind?

No-debt balance-sheet strength, substantial cash, and resilient net margin provide downside support. Successful replacement of lost customer revenue with biopharma OEM sales could restore growth.

Research note

Recommendation

—

Confidence

medium

As of

2026-07-31

Base target

$72

p=50%

Bull target

$80

p=20%

Bear target

$58

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Further pressure from weak sales and litigation costs
Balance-sheet strength and replacement-OEM optionality
No-debt balance-sheet strength, substantial cash, and resilient net margin provide downside support.

BearKey bullets

Analyst estimate revisions, target changes, and attributed post-print market reaction are unavailable because coverage is limited.
Higher litigation expense may persist and dilute operating earnings.
International, neonatal, and Filshie-related demand remains uneven.

WatchKey bullets

Q2 earnings confirm revenue-replacement shortfall

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $72 (p=50%)

Target spread vs base: +11% / -19%

Scenario probabilities

Bull Target: $80 (p=20%)Base Target: $72 (p=50%)Bear Target: $58 (p=30%)

Commentary

T+3 earnings tone is negative on revenue and replacement-customer execution, partially offset by no debt, strong cash, and continued profitability. No trustworthy analyst revision or target-change signal, options data, short-interest data, or post-print reaction attribution is available; social coverage is absent. This supports a monitoring view rather than a high-conviction directional thesis.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

No-debt balance-sheet strength, substantial cash, and resilient net margin provide downside support. Successful replacement of lost customer revenue with biopharma OEM sales could restore growth.

Bear Case

Drivers

Scannable catalysts and supporting factors

Further pressure from weak sales and litigation costs
Balance-sheet strength and replacement-OEM optionality

Scenarios

Bull Target (Scenario probability)

$80 / p=20% prob

Base Target (Scenario probability)

$72 / p=50% prob

Bear Target (Scenario probability)

$58 / p=30% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-31
Q2 earnings confirm revenue-replacement shortfall
UTMD reported Q2 2026 revenue of $8.529 million, down 14.3% year over year, and first-half revenue down 12.3%. Replacement sales from new biopharma customers reached only $211, versus $2.889 million of 2025 sales from two former customers that management expected to recover. [#SEC-8K-2026-07-23]
Prob 100.00% • Move -5.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Further pressure from weak sales and litigation costs
2026-10-29
Lower-than-expected sales left manufacturing overhead underabsorbed, while U.S. litigation costs were $213 thousand higher in Q2 and $341 thousand higher in the first half versus prior-year periods. Persistence would pressure operating margins and earnings.
Prob 65% • Move -8% • Priced-in 55%

Long-term Catalysts

Months to a year

Balance-sheet strength and replacement-OEM optionality
2027-07-31
UTMD ended June with no debt and $87.5 million of cash and investments. Recovery in biopharma OEM sales during the second half could improve growth, but the company characterized the first-half gain as slower than expected.
Prob 45% • Move 12% • Priced-in 45%

Risks

Analyst estimate revisions, target changes, and attributed post-print market reaction are unavailable because coverage is limited.
Higher litigation expense may persist and dilute operating earnings.
International, neonatal, and Filshie-related demand remains uneven.
Lower volume could continue to pressure gross and operating margins through underabsorbed manufacturing costs.
Replacement sales may not offset the loss of the former China distributor and PendoTECH customer.

Peers

Symbol	Summary
ABT	Large diversified medtech benchmark; useful for sector context but not a close size or business-model comparable.
BSX	Large diversified device peer; broad sector benchmark rather than a direct valuation comparable.
EW	Large procedure-focused medtech peer; relevant for industry context but materially different scale and portfolio mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

ABT

Large diversified medtech benchmark; useful for sector context but not a close size or business-model comparable.

BSX

Large diversified device peer; broad sector benchmark rather than a direct valuation comparable.

Large procedure-focused medtech peer; relevant for industry context but materially different scale and portfolio mix.